title: Hesperidin prevents retinal and plasma abnormalities in streptozotocin-induced diabetic rats.
abstract: Diabetic retinopathy is a complex disease that potentially involves increased production of advanced glycosylation end products (AGEs) and elevated aldose reductase (AR) activity, which are related with oxidative stress and inflammation. The aim of this study was to investigate the effects of hesperidin on retinal and plasma abnormalities in streptozotocin-induced diabetic rats. Hesperidin (100, 200 mg/kg daily) was given to diabetic rats for 12 weeks. The blood-retina breakdown (BRB) was determined after  2 weeks of treatment followed by the measurement of related physiological parameters with ELISA kits and immunohistochemistry staining at the end of the study. Elevated AR activity and blood glucose, increased retinal levels of vascular endothelial growth factor (VEGF), ICAM-1, TNF-&#945;, IL-1&#946; and AGEs as well as reduced retina thickness were observed in diabetic rats. Hesperidin treatment signi&#64257;cantly suppressed BRB breakdown and increased retina thickness, reduced blood glucose, AR activity and retinal TNF-&#945;, ICAM-1, VEGF, IL-1&#946; and AGEs levels. Furthermore, treatment with hesperidin signi&#64257;cantly reduced plasma malondialdehyde (MDA) levels and increased SOD activity in diabetic rats. These data demonstrated that hesperidin attenuates retina and plasma abnormalities via anti-angiogenic, anti-inflammatory and antioxidative effects, as well as the inhibitory effect on polyol pathway and AGEs accumulation.
authors.affiliation: State Key Laboratory of Natural Products and Functions, China Pharmaceutical University, Nanjing, China. shixiupu@yahoo.com.cn
authors.forename: Xiupu
authors.initials: X
authors.lastname: Shi
authors.forename: Sha
authors.initials: S
authors.lastname: Liao
authors.forename: Huijuan
authors.initials: H
authors.lastname: Mi
authors.forename: Changrun
authors.initials: C
authors.lastname: Guo
authors.forename: Dongli
authors.initials: D
authors.lastname: Qi
authors.forename: Fei
authors.initials: F
authors.lastname: Li
authors.forename: Chunfeng
authors.initials: C
authors.lastname: Zhang
authors.forename: Zhonglin
authors.initials: Z
authors.lastname: Yang
mesh_terms: D000449:Aldehyde Reductase / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001786:Blood Glucose; D001813:Blood-Retinal Barrier / Q000187:drug effects / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy*; D003930:Diabetic Retinopathy / Q000517:prevention & control*; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006569:Hesperidin / Q000494:pharmacology* / Q000627:therapeutic use; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D018384:Oxidative Stress; D051381:Rats; D017207:Rats, Sprague-Dawley; D012160:Retina / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D013311:Streptozocin; D013482:Superoxide Dismutase / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001786:Blood Glucose; D017127:Glycation End Products, Advanced; D053583:Interleukin-1beta; D014409:Tumor Necrosis Factor-alpha; D042461:Vascular Endothelial Growth Factor A; C467498:vascular endothelial growth factor A, rat; D018799:Intercellular Adhesion Molecule-1; D008315:Malondialdehyde; D013311:Streptozocin; D006569:Hesperidin; D000449:Aldehyde Reductase; D013482:Superoxide Dismutase